Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors J. Powderly M.R. Patel J.J. Lee J. Brody F. Meric-Bernstam E. Hamilton S. Ponce Aix J. Garcia-Corbacho Y-J. Bang M-J. Ahn S.Y. Rha K-P. Kim M. Gil Martin H. Wang A. Lazorchak T. Wyant A. Ma S. Agarwal D. Tuck A. Daud
Title CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study
Journal Ann Oncol.
Vol
Issue
Date
URL https://academic.oup.com/annonc/article/28/suppl_5/mdx376.007/4109221
Abstract Text Ann Oncol. 2017 Sep 18; 28 (Suppl_5): Abstract 1141PD

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
CA-170 CA-170 3 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
CA-170 Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 63 CA-170 is a small molecule inhibitor of PD-L1 (CD274) and V-domain Ig suppressor of T-cell activation (VISTA), which may stimulate T-cell mediated immune response against tumor cells (Ann Oncol. 2017 Sep 18; 28 (Suppl_5): Abstract 1141PD).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown melanoma not applicable CA-170 Preclinical - Cell line xenograft Actionable In a preclinical study, CA-170 activated peripheral T cells and inhibited tumor growth in mouse models of melanoma (Ann Oncol. 2017 Sep 18; 28 (Suppl_5): Abstract 1141PD). detail...
Unknown unknown colon carcinoma not applicable CA-170 Preclinical - Cell line xenograft Actionable In a preclinical study, CA-170 activated peripheral T cells inhibited tumor growth in mouse models of colon carcinoma (Ann Oncol. 2017 Sep 18; 28 (Suppl_5): Abstract 1141PD). detail...
Unknown unknown Advanced Solid Tumor not applicable CA-170 Phase I Actionable In a Phase I trial, CA-170 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, resulting in peripheral T cell activation (Ann Oncol. 2017 Sep 18; 28 (Suppl_5): Abstract 1141PD; NCT02812875). detail...